ReviewOncology reports2025
Lactylation modification in lung cancer: A review of current research and future directions (Review).
Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Research progress on lactate metabolism in lung cancer: Tumorigenesis, drug resistance and clinical translation (Review).Oncology reports · 2026Review
- Development and validation of a radiomics-habitat model for preoperatively predicting poorly differentiated stage IA lung adenocarcinoma.Journal of thoracic disease · 2026Article
- From force to fate: Implications of mechanomemory in lung disease.Respiratory research · 2026Review
- Anatomical distribution and predictors of lymph node metastasis in robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: a multicenter study by the Junior ERUS/YAU Robotic Surgery Working Group.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a common malignancy that poses risks to human health and quality of life. The primary treatment options currently available include surgery, chemotherapy and radiotherapy. However, the aggressive metastatic nature of the disease combined with the development of drug and radiation resistance results in suboptimal survival outcomes. Consequently, there is a need to explore novel therapeutic approaches and develop more effective drugs. Lactylation, an epigenetic modification induced by lactate, alters histone proteins to modify the chromatin structure, as well as non‑histone proteins. This post‑translational modification is associated with the initiation and progression of lung cancer. Lactylation carries out a considerable role in the onset, progression and resistance of the disease by influencing tumor metabolism and the surrounding microenvironment. Targeting lactylation could provide innovative strategies for the targeted therapy of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.